Federated Hermes Inc. Buys 56,930 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Federated Hermes Inc. grew its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 51.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 167,957 shares of the biotechnology company's stock after purchasing an additional 56,930 shares during the period. Federated Hermes Inc. owned approximately 0.08% of BioCryst Pharmaceuticals worth $1,263,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Captrust Financial Advisors increased its position in shares of BioCryst Pharmaceuticals by 19.4% during the 3rd quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company's stock valued at $124,000 after purchasing an additional 2,644 shares during the period. Quantinno Capital Management LP bought a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at about $82,000. Wellington Management Group LLP acquired a new position in shares of BioCryst Pharmaceuticals in the 3rd quarter worth approximately $819,000. Geode Capital Management LLC raised its holdings in shares of BioCryst Pharmaceuticals by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company's stock worth $36,776,000 after purchasing an additional 127,708 shares in the last quarter. Finally, SkyView Investment Advisors LLC lifted its stake in BioCryst Pharmaceuticals by 30.0% during the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 3,000 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Trading Up 2.5 %

NASDAQ:BCRX traded up $0.18 on Friday, hitting $7.40. 3,353,912 shares of the company's stock traded hands, compared to its average volume of 2,805,144. The company has a market cap of $1.55 billion, a PE ratio of -12.13 and a beta of 1.75. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $9.50. The firm has a 50-day moving average price of $7.82 and a 200-day moving average price of $7.73.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analysts' expectations of $126.64 million. During the same quarter in the previous year, the firm earned $0.28 earnings per share. The business's quarterly revenue was up 40.8% compared to the same quarter last year. On average, research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on BCRX. Needham & Company LLC reaffirmed a "buy" rating and issued a $15.00 price target on shares of BioCryst Pharmaceuticals in a report on Thursday, April 10th. Wedbush started coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 target price on the stock. Evercore ISI increased their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a research report on Monday, January 13th. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $11.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, April 11th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $15.57.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.